This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Inside Small-Cap's 3-Year Best Surge in Popularity: ETFs in Focus
by Sanghamitra Saha
Wall Street's newfound bullishness on small caps reflects a notable shift in market dynamics, with several analysts predicting continued growth.
5 Market-Beating Sector ETFs of December
by Sweta Killa
Wall Street sizzled in December, with all three major indices touching a series of new highs.
Best-Performing ETFs of Last Week
by Sanghamitra Saha
The S&P 500 hit a new high for the year last week after the November jobs report and University of Michigan consumer survey data indicated a resilient economy and cooling inflation, triggering bets on a so-called soft-landing scenario.
5 ETF Areas That Spooked Investors in October
by Sanghamitra Saha
After a downbeat September, October too remained volatile for Wall Street due to higher rates.
5 Top-Performing Sector ETFs of Q2
by Sweta Killa
Wall Street is on track to end the second quarter on a positive note. The Nasdaq Composite Index has outperformed, gaining 10.9% since the start of April, while the S&P 500 and the Dow Jones are up 6.6% and 2%, respectively.
Biotech ETFs Pop on M&A Resurgence
by Neena Mishra
2023 could be a year of heightened biotech dealmaking activity
5 Sector ETFs That Beat the Market in April
by Sweta Killa
Wall Street wrapped up a winning April buoyed by better-than-expected earnings and easing of banking fears. Cooling inflation added to the strength. The Dow Jones logged its best monthly gain since January, rising 1.7%, while the S&P 500 rose 1.5%.
5 Best ETF Areas of April Up At Least 10%
by Sanghamitra Saha
April brings with it seasonal tailwinds for the equity world. Digital Assets, Sugar, Platinum, Biotech and Homebuilding were clear winners in the month.
ETFs to Play Biden's 2024 Reelection Campaign Launch
by Sanghamitra Saha
President Joe Biden recently announced his reelection bid. These ETF areas may benefit on that campaign launch.
Best ETF Areas of Last Week
by Sanghamitra Saha
Wall Street offered a flat performance last week. Biotech, platinum and home building were some of the areas that won last week.
Biotech & Crypto -- Best ETF Areas of Last Week
by Sanghamitra Saha
Biotech and cryptocurrency -- two ETF areas outperformed last week.
Biotech Wins Last Week: 5 Best ETFs
by Sweta Killa
The biotech corner of the broad healthcare sector outperformed last week on speculation over a takeover bid for Global Blood Therapeutics.
The Zacks Analyst Blog Highlights BBC, CNCR XBI, BBP, and SBIO
by Zacks Equity Research
BBC, CNCR, XBI, BBP, and SBIO are part of Zacks top Analyst Blog.
5 ETFs Riding High on the Biotech Comeback
by Sweta Killa
Biotech, the downtrodden segment of the market, has made a solid comeback on bargain hunting.
Biotech ETFs That Outperformed Last Week
by Sweta Killa
Biotech ETFs was the biggest gainer last week.
Healthcare Emerges as Best Sector of Last Week: 5 Top ETFs
by Sanghamitra Saha
Wall Street was downbeat last week with all indexes in the red. Still, Healthcare sector emerged as a key winner last week.
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?
by Zacks Equity Research
Sector ETF report for SBIO
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?
by Zacks Equity Research
Sector ETF report for SBIO
September Turns Sour: Top ETF Areas of Last Week
by Sanghamitra Saha
Wall Street ended on a negative note last week just the week before that, strengthening the worth of the adage that September is historically the worst month of the year for stocks.
5 Sector ETFs That Beat the Market in August
by Sweta Killa
Most of the rally was powered by a huge vaccination drive, upbeat corporate earnings and the Fed's dovish comments that have renewed optimism for sustained global economic recovery.
Best Small/Mid-Cap ETFs of Last Week
by Sanghamitra Saha
The Russell 2000 Index was a winner last week. These ETFs gained immensely last week.
Healthcare ETFs Surge on FDA Full-Vaccine Nod & Deal News
by Sweta Killa
The FDA granted full approval of a COVID-19 vaccine made by Pfizer (PFE) and BioNTech that could accelerate inoculations in the United States.
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?
by Zacks Equity Research
Sector ETF report for SBIO
Top-Performing Biotech ETFs of Last Week
by Sweta Killa
Investors may want to tap the bullishness in the sector with the best biotech ETFs of last week.
5 Small-Cap Sector ETFs Leading the Russell 2000 Rally
by Sweta Killa
We have presented five ETFs from different sectors that have easily crushed the Russell 2000 Index over the past month.